Innovent Biologics grants employee share options, restricted shares under 2024 scheme

Innovent Biologics Inc. granted 15,000 share options to three non-connected employees and 148,200 restricted shares to 29 non-connected employees on December 5, 2025. These grants, made under the 2024 Share Scheme, aim to incentivize and retain eligible participants by aligning their interests with the company's long-term growth.

The granted options have an exercise price of HK$93.62 per share, determined by the higher of the closing price on the grant date, the average closing price over the five preceding business days, or the nominal value. The restricted shares have a market value of approximately HK$13,634,400, based on a closing price of HK$92.00 per share on the grant date.

Both the options and restricted shares will vest in two tranches: 75% on December 5, 2028, and 25% on December 5, 2029. Vesting is contingent upon individual annual performance targets set against benchmarks relevant to their respective functions, which include research and development, commercialization, and supporting roles. The company also detailed clawback mechanisms for both types of grants under specific circumstances, such as termination for cause or serious misconduct.